NewGenIvf Group Ltd (NIVF) Form 6-K — Sep 30, 2026
NewGenIvf Group (NASDAQ: NIVF) closed a best-efforts public offering on September 30, 2026, raising approximately $1.25 million gross before fees. The offering comprised 17,857,143 Class A Ordinary Shares or pre-funded warrants — 125,000 shares plus pre-funded warrants on 17,732,143 shares — priced at $0.07 per share ($0.06999 per warrant), an extremely dilutive near-penny-stock price for the micro-cap. Aegis Capital Corp. acted as exclusive placement agent, earning an 8.0% cash fee on gross proceeds plus expense reimbursements including $100,000 for its counsel, and holds a 12-month right of first refusal on future financings.
Key figures
- Gross Proceeds
- 1250000
- Offering Price
- 0.07
- Shares Offered
- 17857143
- Counsel fee
- $100,000 for Aegis's counsel legal fees
- Rofr period
- 12 months after commencement of sales
- Lockup period days
- 60
- Ordinary shares sold
- 125000
- Standstill period days
- 60
- Placement agent fee pct
- 8.0% of gross proceeds
- Pre funded warrant price
- $0.06999
- Pre funded warrant shares
- 17732143
- Pre funded warrant exercise price
- 0.00001
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.